A pivotal publication detailing the use of oral relugolix for androgen-deprivation therapy in advanced prostate cancer was released on 2020-01-01. The publication, titled "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer," describes a study evaluating the safety and efficacy of relugolix in men with this condition.
Background
Relugolix is investigated for its role in androgen-deprivation therapy for patients with advanced prostate cancer. This therapeutic approach aims to reduce the levels of androgens, which can fuel the growth of prostate cancer cells.
What this means
The publication of this pivotal study provides clinicians and researchers with detailed information regarding the use of oral relugolix as an androgen-deprivation therapy for advanced prostate cancer. While specific numerical outcomes are not detailed in the provided summary, the publication focuses on the safety and efficacy profile of relugolix in this patient population. This information is crucial for understanding the therapeutic potential and clinical application of relugolix in managing advanced prostate cancer.
Source
The information for this article is derived from a pivotal publication titled "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer," which was published in the N Engl J Med. This publication became available on 2020-01-01 and is indexed on PubMed, accessible via pubmed.ncbi.nlm.nih.gov.